Hyperion DeFi (NASDAQ:HYPD) and Wesana Health (OTCMKTS:WSNAF) Head-To-Head Survey

Hyperion DeFi (NASDAQ:HYPD) and Wesana Health (OTCMKTS:WSNAF) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Profitability

This table compares Hyperion DeFi and Wesana Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-138.16%	-94.12%
Wesana Health	N/A	N/A	N/A

Insider and Institutional Ownership

25.8% of Hyperion DeFi shares are owned by institutional investors. 10.9% of Hyperion DeFi shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Hyperion DeFi and Wesana Health”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810,000.00	34.50	-$45.31 million	($4.04)	-0.85
Wesana Health	N/A	N/A	N/A	N/A	N/A

Wesana Health has lower revenue, but higher earnings than Hyperion DeFi.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Hyperion DeFi and Wesana Health, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	1	1	2	0	2.25
Wesana Health	0	0	0	0	0.00

Hyperion DeFi currently has a consensus price target of $5.88, suggesting a potential upside of 71.78%. Given Hyperion DeFi’s stronger consensus rating and higher possible upside, analysts plainly believe Hyperion DeFi is more favorable than Wesana Health.

Summary

Hyperion DeFi beats Wesana Health on 6 of the 8 factors compared between the two stocks.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

About Wesana Health

Wesana Health Holdings Inc. does not have significant operations. Previously, it was developing evidence-based formulations and protocols that empower patients to overcome neurological, psychological, and mental health ailments caused by trauma. The company is headquartered in Chicago, Illinois.